Usability and acceptability of self-testing for hepatitis C virus infection among the general population in the Nile Delta region of Egypt.
Acceptability
HCV
Hepatitis C virus
Rapid diagnostic tests
Self-test
Usability
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
22 06 2021
22 06 2021
Historique:
received:
25
01
2021
accepted:
28
05
2021
entrez:
23
6
2021
pubmed:
24
6
2021
medline:
2
7
2021
Statut:
epublish
Résumé
Self-testing for hepatitis C virus antibodies (HCVST) may be an additional strategy to expand access to hepatitis C virus (HCV) testing and support elimination efforts. We conducted a study to assess the usability and acceptability of HCVST among the general population in a semi-rural, high-HCV prevalence region in Egypt. An observational study was conducted in two hospitals in the Nile Delta region. A trained provider gave an in-person demonstration on how to use the oral fluid HCVST followed by observation of the participant performing the test. Usability was assessed by observing errors made and difficulties faced by participants. Acceptability of HCV self-testing was assessed using an interviewer-administered semi-structured questionnaire. Of 116 participants enrolled, 17 (14.6%) had received no formal education. The majority (72%) of participants completed all testing steps without any assistance and interpreted the test results correctly. Agreement between participant-reported HCVST results and interpretation by a trained user was 86%, with a Cohen's kappa of 0.6. Agreement between participant-reported HCVST results and provider-administered oral fluid HCV rapid test results was 97.2%, with a Cohen's kappa of 0.75. The majority of participants rated the HCVST process as easy (53%) or very easy (44%), and 96% indicated they would be willing to use HCVST again and recommend it to their family and friends. Our study demonstrates the high usability and acceptability of oral fluid HCVST in a general population. Further studies are needed to establish the optimal positioning of self-testing alongside facility-based testing to expand access to HCV diagnosis in both general and high-risk populations.
Sections du résumé
BACKGROUND
Self-testing for hepatitis C virus antibodies (HCVST) may be an additional strategy to expand access to hepatitis C virus (HCV) testing and support elimination efforts. We conducted a study to assess the usability and acceptability of HCVST among the general population in a semi-rural, high-HCV prevalence region in Egypt.
METHODS
An observational study was conducted in two hospitals in the Nile Delta region. A trained provider gave an in-person demonstration on how to use the oral fluid HCVST followed by observation of the participant performing the test. Usability was assessed by observing errors made and difficulties faced by participants. Acceptability of HCV self-testing was assessed using an interviewer-administered semi-structured questionnaire.
RESULTS
Of 116 participants enrolled, 17 (14.6%) had received no formal education. The majority (72%) of participants completed all testing steps without any assistance and interpreted the test results correctly. Agreement between participant-reported HCVST results and interpretation by a trained user was 86%, with a Cohen's kappa of 0.6. Agreement between participant-reported HCVST results and provider-administered oral fluid HCV rapid test results was 97.2%, with a Cohen's kappa of 0.75. The majority of participants rated the HCVST process as easy (53%) or very easy (44%), and 96% indicated they would be willing to use HCVST again and recommend it to their family and friends.
CONCLUSION
Our study demonstrates the high usability and acceptability of oral fluid HCVST in a general population. Further studies are needed to establish the optimal positioning of self-testing alongside facility-based testing to expand access to HCV diagnosis in both general and high-risk populations.
Identifiants
pubmed: 34158006
doi: 10.1186/s12889-021-11169-x
pii: 10.1186/s12889-021-11169-x
pmc: PMC8218412
doi:
Substances chimiques
Hepatitis C Antibodies
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1188Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Références
Diagn Microbiol Infect Dis. 2019 Oct;95(2):149-151
pubmed: 31204109
Virol J. 2020 Jan 31;17(1):14
pubmed: 32005264
BMC Infect Dis. 2018 Jun 19;18(1):281
pubmed: 29914381
BMC Infect Dis. 2017 Nov 1;17(Suppl 1):699
pubmed: 29143676
Lancet. 2000 Mar 11;355(9207):887-91
pubmed: 10752705
N Engl J Med. 2020 Mar 19;382(12):1166-1174
pubmed: 32187475
J Hepatol. 2016 Oct;65(1 Suppl):S46-S66
pubmed: 27641988
Value Health. 2020 Jul;23(7):870-879
pubmed: 32762988
Lancet Glob Health. 2021 Apr;9(4):e431-e445
pubmed: 33639097
J Int AIDS Soc. 2017 May 15;20(1):21594
pubmed: 28530049
J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):449-53
pubmed: 17554213
Clin Microbiol Infect. 2016 May;22(5):459.e1-6
pubmed: 26806260
Lancet HIV. 2018 Jun;5(6):e277-e290
pubmed: 29703707
AIDS. 2017 Jul 1;31 Suppl 3:S203-S212
pubmed: 28665878
Open AIDS J. 2017 Nov 21;11:101-118
pubmed: 29290887
PLoS One. 2020 Jan 14;15(1):e0227198
pubmed: 31935228
J Hepatol. 2020 Apr;72(4):658-669
pubmed: 31734097
PLoS Med. 2011 Oct;8(10):e1001102
pubmed: 21990966
AIDS Behav. 2014 Jul;18 Suppl 4:S422-32
pubmed: 24947852
AIDS Behav. 2015 Nov;19(11):1949-65
pubmed: 26054390
J Infect Public Health. 2018 Jan - Feb;11(1):126-129
pubmed: 28684223
Clin Liver Dis (Hoboken). 2020 Jan 29;14(6):203-206
pubmed: 32015869
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
J Int AIDS Soc. 2016 Sep 12;19(1):20993
pubmed: 27630096
AIDS Patient Care STDS. 2020 Apr;34(4):147-156
pubmed: 32324482